Clinical trial
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After…
NCT00219726 · Poitiers University Hospital, Other · Completed
Key facts
| NCT number | NCT00219726 |
|---|---|
| Title | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation |
| Official title | Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase in Relapse After Allogeneic Stem Cell Transplantation |
| Lead sponsor | Poitiers University Hospital, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib mesylate |
| Enrollment | 30 |
| Start date | May 1, 2002 |
| Completion | Jul 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Aug 29, 2012 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: